m^(6)A去甲基化酶FTO调控BCL2 mRNA稳定性与翻译效率促进血小板前体形成  

m^(6)A demethylase FTO rgulates BCL2 mRNA stability and translation efficiency and thereby promotes proplatelet formation

作　　者：夏文军 卢尧[2] 吴煌 文爱清[2] 陈卫[1] XIA Wenjun;LU Yao;WU Huang;WEN Aiqing;CHEN Wei(Department of Pathophysiology,School of Basic Medicine and Forensic Medicine,North Sichuan Medical College,Nanchong,Sichuan;Department of Transfusion Medicine,State Key Laboratory of Trauma and Chemical Poisoning,Army Medical Center of PLA/Daping Hospital of Third Military Medical University,Chongqing,China)

机构地区：[1]川北医学院基础医学与法医学院病理生理学教研室,四川南充 [2]陆军特色医学中心(第三军医大学大坪医院)输血医学科,创伤与化学中毒全国重点实验室,重庆

出　　处：《陆军军医大学学报》2025年第6期519-530,共12页Journal of Army Medical University

基　　金：国家自然科学基金面上项目(82170134)。

摘　　要：目的探究下调m^(6)A去甲基化酶脂肪质量和肥胖相关基因(fat mass and obesityassociated protein,FTO)对MEG-01巨核细胞系血小板前体形成的影响及其机制。方法①分别用1 nmol/L佛波迷酯(phorbol myristate acetate,PMA)组(诱导组)和DMSO组(对照组)处理MEG-01细胞72 h,通过Western blot和RT-qPCR检测FTO蛋白和mRNA表达变化情况。②用靶向FTO的病毒液(sh-FTO)和阴性对照病毒液(sh-NC)感染MEG-01细胞,用1 nmol/L PMA诱导sh-NC组和sh-FTO组MEG-01细胞72 h后,Western blot和RT-qPCR检测FTO蛋白和mRNA表达变化情况。碘化丙啶(propidium lodrde,PI)DNA染色检测细胞周期、CCK-8检测细胞活力,Annexin V-FITC/PI双染、TUNEL染色检测细胞凋亡情况,Western blot检测cleaved Caspase-3蛋白表达量,CD41/CD61染色检测巨核细胞成熟情况,明场观察和CD61免疫荧光检测血小板前体形成情况,RT-qPCR检测细胞凋亡相关分子(Caspase-3、BAD、BAK1、BCL2、MCL1)表达量,Western blot检测进一步验证BCL2蛋白变化情况,基因表达综合数据库(gene expression omnibus,GEO)中筛选出数据集;使用加州大学圣克鲁兹分校基因组浏览器(University of California,Santa Cruz genome browser,UCSC)分析比对BCL2 mRNA上的甲基化测序峰;m^(6)A甲基化RNA免疫共沉淀(m^(6)A RNA immunoprecipitation,m^(6)A-RIP)验证MEG-01巨核细胞BCL2 mRNA m^(6)A甲基化富集水平,检测sh-NC组和sh-FTO组BCL2 mRNA m^(6)A甲基化富集水平变化,以mRNA半衰期实验和多聚核糖体分离实验检测BCL2 mRNA翻译效率。结果①与DMSO组相比,PMA组FTO蛋白(P<0.05)和mRNA(P<0.01)表达水平升高;②与sh-NC组相比,sh-FTO组FTO mRNA和蛋白表达水平明显降低(P<0.01),细胞周期发生G1/S期阻滞[(60.80±1.29)%vs(72.13±1.18)%,P<0.01],细胞活力明显降低[(1.17±0.03)%vs(0.69±0.05)%,P<0.05],Annexin V-FITC/PI阳性细胞占比升高[(12.87±0.83)%vs(17.45±1.58)%,P<0.01],TUNEL阳性细胞占比显著升高[(1.03±0.27)%vs(17.49±9.91)%,P<0.01],cleaved Caspase-3蛋白表Objective To investigate the effects and underlying mechanisms of down-regulating m^(6)A demethylase fat mass and obesity-associated protein(FTO)on proplatelet formation in the MEG-01 megakaryocytic cells.Methods①MEG-01 cells were treated with 1 nmol/L phorbol myristate acetate(PMA)(treatment group)or DMSO(control group)for 72 h.FTO expression was measured by Western blotting and RT-qPCR.②MEG-01 cells were infected with targeted FTO shRNA(knockdown group,sh-FTO)or negative control shRNA(negative control group,sh-NC)viruses.FTO knockdown group and negative control group MEG-1 cells were treated with 1 nmol/L PMA for 72 h,and the protein and mRNA expression levels of FTO were detected by Western blotting and RT-qPCR.Cell cycle,viability and apoptosis were assessed by propidium iodide(PI)DNA staining,CCK-8 assay and Annexin V-FITC/PI double staining and TUNEL staining.The expression of cleaved Caspase-3 protein was determine by Western blotting.Megakaryocyte maturation was assessed by CD41/CD61 staining.Proplatelet formation was observed under bright field and detected by CD61 immunofluorescence assay.The expression of apoptosis-related molecules(Caspase3,BAD,BAK1,BCL2 and MCL1)was detected by RT-qPCR,and the protein change of BCL2 was further verified by Western blotting.The dataset was screened out from the gene expression omnibus(GEO)database,and then analyzed with University of California,Santa Cruz(UCSC)genome browser to compare the methylation sequencing peaks on BCL2 mRNA,and m^(6)A methylated RNA immunoprecipitation(m^(6)A-RIP)was used to assess the m^(6)A methylation levels of BCL2 target gene mRNAs in MEG-01 megakaryocytes.Then,the changes in the m^(6)A methylation enrichment level of BCL2 mRNA were observed between the sh-NC group and the sh-FTO group.mRNA stability and ribosome profiling assays were performed to assess translational efficiency of target genes.Results①PMA treatment upregulated the expression of FTO at protein(P<0.05)and mRNA(P<0.01)levels.②FTO shRNA resulted in reduced FTO express

关 键 词：脂肪质量和肥胖相关基因 血小板前体 m^(6)A甲基化修饰 B淋巴细胞瘤-2基因 

分 类 号：R329.25[医药卫生—人体解剖和组织胚胎学] R331.143[医药卫生—基础医学] R394.3